PMGC Holdings Fully Utilizes $20M Equity Facility and Provides Update on EL-22 Phase 2 IND Path

On April 8, 2026, PMGC Holdings Inc. (NASDAQ: ELAB) announced that it has fully utilized its $20 million equity purchase facility with Streeterville Capital, LLC. The completion of this financing strengthens the company's cash position as it executes a multi-sector acquisition strategy. PMGC has recently expanded its portfolio through the acquisitions of Pacific Sun Packaging, AGA Precision Systems, Indarg Engineering, and SVM Machining, targeting sectors such as aerospace, defense, semiconductors, and medical devices. Beyond its industrial holdings, PMGC highlighted the continued advancement of its biopharmaceutical subsidiary, Northstrive Biosciences Inc. The subsidiary is developing a multi-asset pipeline focused on muscle preservation and obesity management in conjunction with GLP-1 receptor agonist therapies. A key priority is the FDA-supported path for its lead candidate, EL-22, toward a Phase 2 Investigational New Drug (IND) submission. The company remains focused on organic growth, integrating recent acquisitions, and evaluating further accretive M&A opportunities to drive shareholder value.